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Excited (or agitated) delirium is characterized by agitation, aggression, acute distress and sudden 
death, often in the pre-hospital care setting. It is typically associated with the use of drugs that alter 
dopamine processing, hyperthermia, and, most notably, sometimes with death of the affected person 
in the custody of law enforcement. Subjects typically die from cardiopulmonary arrest, although the 
cause is debated. Unfortunately an adequate treatment plan has yet to be established, in part due to 
the fact that most patients die before hospital arrival. While there is still much to be discovered about 
the pathophysiology and treatment, it is hoped that this extensive review will provide both police and 
medical personnel with the information necessary to recognize and respond appropriately to excited 
delirium. [West J Emerg Med. 2011;12(1):77-83.]
INTRODUCTION
Excited delirium (EXD), first described in the mid 
1800’s, has been referred to by many other names – Bell’s 
mania, lethal catatonia, acute exhaustive mania and agitated 
delirium.1 Regardless of the label used, all accounts describe 
almost the exact same sequence of events: delirium with 
agitation (fear, panic, shouting, violence and hyperactivity), 
sudden cessation of struggle, respiratory arrest and death.2 
In the majority of cases unexpected strength and signs of 
hyperthermia are described as well.3,4.While the incidence of 
EXD is not known, the purpose of this review is to identify 
what is known or suspected about the pathophysiology, 
outcomes and management options associated with EXD to 
assist medical professionals in the future.
Issues Regarding EXD
EXD has gained increasing public attention recently due 
to the number of post-mortem explanations offered by medical 
examiners regarding the death of individuals being restrained 
by police or being taken into custody. This diagnosis has 
caused concern because EXD is not a currently recognized 
medical or psychiatric diagnosis according to either 
the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IVTR) of the American Psychiatric Association or the 
International Classification of Diseases (ICD-9) of the World 
Health Organization. Likewise, the authors of one review 
article found enough evidence in the literature to suggest that 
excited delirium, rhabdomyolysis and neuroleptic malignant 
syndrome might represent the clinical spectrum of a single 
disease.5 Although more research is needed to elucidate cause 
and effect, it is important to note that a lack of recognition 
of the condition in the context of law enforcement activities 
does not negate the significance of the behavioral and physical 
signs referred to as EXD. For instance, one important study 
found that only 18 of 214 individuals identified as having 
EXD died while being restrained or taken into custody.6 If 
anything, the possible association with other life-threatening 
syndromes only gives impetus to the need for critical 
emergency medical intervention when encountering a person 
thought to be in a state of excited delirium.
Background
Although reports of patients with similar symptoms first 
appeared in the 19th century, the first modern mention of EXD 
was in 1985.3 The presentation of excited delirium occurs with 
a sudden onset, with symptoms of bizarre and/or aggressive 
behavior, shouting, paranoia, panic, violence toward 
others, unexpected physical strength and hyperthermia. An 
extensive review of reported case series reveals that in a 
majority of cases EXD was precipitated by stimulant drug 
use and in much fewer cases psychiatric illness (such as 
mania, depression, or schizophrenia) or systemic illness.7-9 Western Journal of Emergency Medicine  78  Volume XII, no. 1  :  February 2011
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Methamphetamine, PCP and LSD have been reported in a 
few series, but by far the most prevalent drug of abuse found 
on toxicology screening was cocaine.10 Since the victims 
frequently die while being restrained or in the custody of 
law enforcement, there has been speculation over the years 
of police brutality being the underlying cause. However, it 
is important to note that the vast majority of deaths occur 
suddenly prior to capture, in the emergency department (ED), 
or unwitnessed at home.
Prior to 1985 most reported cases of sudden death 
from cocaine intoxication involved “body stuffers” who 
died secondary to massively high exposure to the drug after 
packets they were carrying burst. A report published by 
Wetli and Fishbain 3 in 1985 was one of the first case series 
to examine recreational cocaine users who died following 
episodes of excited delirium. They noticed that these deaths 
differed in both presentation and average blood cocaine 
concentrations from typical cocaine overdose fatalities. In 
fact, cases of agitated delirium were often associated with 
lower blood levels of cocaine. Explorations by Pollanen 
et al9 and Ruttenber et al11 showed blood levels of cocaine 
in EXD cases to be similar to levels found in recreational 
cocaine users and much lower than levels found in people 
who died from cocaine associated intoxication. Moreover, the 
reports found that the blood levels of benzoylecgonine, the 
primary metabolite of cocaine, in the cocaine-associated EXD 
cases were higher than in recreational users, suggesting the 
cocaine use prior to death was consistent with recent “binge” 
use. More recently, Stephens et al.,12 in an analysis of the 
significance of cocaine upon a specific death, confirmed that 
a pattern of chronic cocaine use characterized by repeated 
binges is associated with the development of fatal EXD.
PATHOPHYSIOLOGY
Cocaine has many neurotransmitter affects on the brain, 
including the blockade of all monamine neurotransmitters via 
its interaction with the various transporters. The reinforcing 
or addictive properties of cocaine are primarily attributed 
to increased dopamine levels. Dopamine is an essential 
neurotransmitter in several neural pathways regulating 
movement, hypothalamic function, positive behavioral 
reinforcement and higher cognitive function. The mesolimbic 
pathway, which connects the nucleus accumbens and 
tegmentum, is most critical for reinforcement and addiction 
to psycho-stimulants. Several researchers have suggested that 
cocaine use may cause aberrant dopamine processing in the 
mesolimbic pathway and elsewhere in the brain, resulting 
in hyperactivity and hyperthermia.11,13 Additionally, in cases 
of EXD, dopamine processing has been shown to be further 
altered compared to non-psychotic cocaine users. Recent 
research has identified several possible explanations for this 
critical difference. 
First, Mash et al14 discovered evidence of increased 
alpha α-synuclein, a native protein and major component of 
Lewy bodies in Parkinson’s disease, in midbrain dopamine 
neurons of chronic non-psychotic cocaine users.2 In vivo, 
increased binding of α-synuclein to dopamine transporters 
has been shown to increase dopamine uptake and dopamine 
mediated apoptosis, leading to irreversible neuroadaptive 
changes. The authors suggested that the increased α-synuclein 
deposition might occur as a protective response due to high 
dopamine recycling and oxidative stress from cocaine abuse. 
Their postmortem research demonstrated that chronic non-
psychotic cocaine users, compared to control non-drug users, 
had markedly elevated presynaptic α-synuclein levels in the 
substantia nigra and ventral tegmental area of the midbrain. 
However, compared to the same control group, victims of fatal 
EXD showed decreased levels of α-synuclein in the substantia 
nigra and only slightly increased levels in the ventral 
tegmental area. This discovery suggests that EXD victims 
might have a different pattern of α-synuclein regulation and 
perhaps lack normal compensatory measures for dealing with 
rapidly elevating dopamine levels.  
Second, multiple studies have documented dopamine 
transporter binding sites that are increased in human chronic 
cocaine users.15-17 Mash et al18 used in vitro autoradiography 
and ligand binding studies to map and measure D3 dopamine 
and kappa 2 opioid receptors in brain tissue from postmortem 
cocaine overdose victims and compared them to fatal 
EXD victims. The D3 receptor subtype has a distinctive 
neuroanatomy pattern in the normal human brain, with 
high densities in areas associated with the pattern-building, 
euphoric effects of cocaine, such as, the nucleus accumbens 
and limbic sectors of caudate and putamen. The authors found 
that chronic cocaine abuse lead to an adaptive elevation of D3 
dopamine receptors (2-3 times vs. control) and kappa 2 opioid 
receptors (2 times vs. control) in the nucleus accumbens and 
associated limbic regions. By contrast, cocaine abusing EXD 
victims did not demonstrate increased density for D3 receptor 
binding. This finding mirrored similar results by Staley et 
al19 that failed to demonstrate an elevation in dopamine 
transporters in the striatum of EXD victims versus aged-
matched drug-free control patients. Mash et al18 suggested that 
the lack of compensatory changes in the EXD victims could 
be related to concurrent psychiatric co -morbidity, recent 
“binge” cocaine use, or aberrant molecular processing of D3 
receptor mRNA. Interestingly, different mRNA species have 
been found in the cerebral cortices of chronic schizophrenia 
patients, which raise the possibility that similar alterations in 
D3 receptor processing could be involved in EXD victims.20
Third, further investigation by Mash et al22 focused 
on the functional activity of dopamine transporters, which 
were previously found to be elevated in the limbic system 
of chronic cocaine abusers.18,21 Using cryopreserved tissue 
samples from aged-matched chronic cocaine users (n=10), 
EXD victims (n=8) and control subjects (n=10), the authors 
quantified the number of dopamine transporters in parallel 
to dopamine uptake and discovered dopamine uptake was Volume XII, no. 1  :  February 2011  79  Western Journal of Emergency Medicine
twofold in the ventral striatum from chronic cocaine users 
versus aged-matched controls. Victims of fatal EXD failed 
to demonstrate an increase in dopamine transport function, 
despite having a history of cocaine use and post-mortem blood 
elevations of cocaine and benzoylecgonine. Based on the 
results, chronic cocaine use seems to cause a compensatory 
increase in dopamine transporters, which would decrease the 
amount of dopamine available to potentially over stimulate 
the post-synaptic receptors. This effect, which may be neuron 
protective, is lacking in fatal EXD victims.
In addition to altering dopamine reuptake directly, cocaine 
has been shown to potently inhibit serotonin reuptake, thus 
elevating synaptic levels of the neurotransmitter.22 Despite 
the relative certainty that dopamine is the primary substrate 
mediating the reinforcing and addictive properties of cocaine, 
a study by Rocha et al23 of dopamine transporter knockout 
mice suggests the involvement of serotonergic brain regions in 
the initiation and maintenance of cocaine self-administration 
and withdrawal symptoms. Meanwhile, serotonin has been 
implicated as an independent modulator of dopaminergic 
neurotransmission. Mash et al24 compared serotonin 
transporter density in brain tissue from cocaine overdose 
victims and cocaine-associated EXD victims, finding that the 
transporters localized to the dopamine rich substantia nigra 
and striatum in response to chronic cocaine use. Once again, 
EXD victims failed to display an up regulation of serotonin 
transporters within aforementioned brain regions. 
Lastly, in a 2009 case series of an unprecedented ninety 
fatal EXD victims, Mash et al25 conducted a post-mortem 
quantitative analysis of dopamine transporters and heat shock 
protein 70. Incident circumstances, force measures, autopsy 
and toxicology results were determined and controlled in 
the analysis. Mean core body temperature among the ninety 
victims was 40.7°Celsius and, although the majority tested 
positive for cocaine, four had no licit or illicit drugs or 
alcohol found at autopsy. The authors discovered heat shock 
proteins were elevated 1.8-4 fold in postmortem brain tissue, 
confirming that hyperthermia is an associated symptom and 
indication of fatal autonomic dysfunction in the victims. 
In addition, dopamine transporter levels were decreased 
compared to age-matched controls, which correlate with the 
findings by previous authors of aberrant dopamine signaling in 
EXD.
These observations demonstrate that cocaine affects a 
number of different neurochemical substrates in the brain 
and suggest that chronic exposure may lead to complex 
neuroadaptations within discrete brain loci. Furthermore, 
compared to non-psychotic cocaine overdose victims, fatal 
EXD victims have been shown to possess alterations in 
neuroanatomy and neurophysiology that may represent a 
subtype of patient with an altogether unusual genotype and/
or phenotype; one characterized by high dopamine levels and 
a hyperactive autonomic nervous system. This understanding 
may lead to changes in the recognition, handling and 
Takeuchi et al.  Excited Delirium
acute treatment of EXD by first responders and emergency 
physicians.   
OUTCOMES
Approximately two thirds of EXD victims die at the 
scene or during transport by paramedics or police.26 Victims 
who do not immediately come to police attention are often 
found dead in the bathroom surrounded by wet towels and/or 
clothing and empty ice trays, apparently succumbing during 
failed attempts to rapidly cool down.2 It appears that in all 
cases, victims died of either respiratory arrest or fatal cardiac 
dysrrhythmia. Diagnoses were supported by postmortem 
exams showing pulmonary and cerebral edema with nonlethal 
self-inflicted injuries.3,10,27,28 The few who live long enough to 
be hospitalized often succumb to disseminated intravascular 
coagulation, rhabdomyolysis and renal failure.2 These fatal 
cardiopulmonary changes are thought to be the result of 
increased catecholamine stress on the heart, myocardial 
hypertrophy, microangiopathy and fatal arrhythmias.3,10 The 
proposed cause of these changes is debated.
Since the victims sometimes die in police custody, the 
most widely publicized proposed causes of death in EXD are 
taser use and positional asphyxia. No study thus far has been 
able to demonstrate a causal relationship between Taser use 
and subsequent individuals’ deaths.10,28 In one study of 32 
healthy police volunteers, a 12-lead electrocardiogram was 
performed at baseline and then repeated within 60 seconds 
post-exposure to a one to five second shock by the Taser 
X26.29 The authors reported no instances of dysrhythmia 
nor ectopy among the subjects. Furthermore, no statistically 
significant changes were noted in the QRS duration, QT and 
QTc intervals. These results corroborate with previous reports 
using single-lead monitoring to assess cardiac changes before, 
during, and after Taser activation.30,31
As mentioned before, people experiencing EXD are 
highly agitated, violent, and show signs of unexpected 
strength so it is not surprising that most require physical 
restraint. The prone maximal restraint position (PMRP, also 
known as “hobble” or “hogtie”), where the person’s ankles 
and wrists are bound together behind their back, has been used 
extensively by field personnel. In far fewer cases, persons 
have been tied to a hospital gurney or manually held prone 
with knee pressure on the back or neck.6,9,10,26 Supporters of the 
positional asphyxia hypothesis postulate that an anoxic death 
results from the combination of increased oxygen demand 
with a failure to maintain a patent airway and/or inhibition of 
chest wall and diaphragmatic movement.9,10 This explanation 
has been further supported by coroners’ reports of “positional 
asphyxia” as the cause of death in multiple fatal EXD cases.
The positional asphyxia theory has been refuted by a 
series of articles by Chan et al32 exploring the effect of PRMP 
on ventilatory capacity and arterial blood gases. In one study 
of fifteen healthy male volunteers, the authors found a small, 
but statistically significant decline in forced vital capacity Western Journal of Emergency Medicine  80  Volume XII, no. 1  :  February 2011
(FVC), forced expiratory volume in one second (FEV1) 
and maximal minute ventilation (MVV) comparing sitting 
to restrained positions. However, there was no evidence of 
hypoxia (mean oxygen tension [PO2] less than 95 mmHg 
or co-oximetry less than 96%) in either position, nor was 
there a significant difference in PCO2, heart rate recovery 
or oxygen saturation. In another study, the authors sought 
to determine the effect of adding 25 and 50 pounds weight 
force on respiratory function of healthy volunteers in the 
PRMP.33 Validating earlier results, they found FVC/FEV1 
was significantly lower in restrained positions versus sitting, 
but not significantly different between restrained positions 
with and without weight force. Furthermore, they found mean 
oxygen saturation levels were above 95% and mean end-tidal 
CO2 levels were below 45 mmHg for all positions, regardless 
of weight force. Based on these findings, PMRP may result 
in a transient pattern of restricted pulmonary function, 
but the lack of evidence for hypoxia or hypoventilation 
suggests that factors other than body positioning appear to 
be more important determinants for sudden, unexpected 
death. Nonetheless, respiratory muscle fatigue resulting 
from exertion and struggle against restraints (exertion vs. 
position asphyxia) cannot be excluded nor can potentially fatal 
pre-existing problems with central cardiac output, oxygen 
saturation, or oxygen use.6,26,28,34
Another potential cause of death is cardio toxicity 
due to chronic cocaine abuse. Preexisting coronary artery 
disease appears to account for many of the deaths, as does 
the contribution of cocaine acting as a potent adrenergic 
agonist, but the mechanism is likely more complex.27 A 
larger case series published in 2006 noted that more than 
half of EXD fatalities were found to have some degree 
of cardiovascular disease.28 Since the majority of deaths 
occur after prolonged drug use, it is thought that cocaine 
initiates a series of detrimental changes to the heart that 
might take years to express. These changes may be due 
to long-term catecholamine toxicity and include cardiac 
hypertrophy, microangiopathy and myocardial fibrosis.35 
Electrocardiographic and autopsy studies confirm that the 
heart weight of cocaine users, is, on average, ten percent 
greater than expected values.36,37 It is not clear how cocaine 
initiates the process of hypertrophy, but it could be due 
to the direct oxidant effect of cocaine or cocaine-induced 
hypertension. Either way, research using rats injected with 
cocaine demonstrated increases in levels of mRNA coding for 
atrial naturetic factor, collagen and alpha/beta myosin.38
Small intramyocardial arteries are often thickened 
in cocaine users. It is hypothesized that cocaine-induced 
apoptosis damages the muscular layer of the small vessels 
or that the damage is once again due to the direct oxidant 
effect of cocaine.39 The smaller artery lumen may lead to a 
mismatch in blood flow supply-demand, and ultimately under 
perfusion whereby the myocardium is not receiving enough 
blood and becomes ischemic. Lastly, cocaine users’ hearts 
often resemble those of patients with heart failure secondary 
to pheochromocytoma. The high levels of catecholamine, 
particularly norepinepherine, seem to induce a diffuse pattern 
of discrete fibrotic lesions, which tend to favor reentry and the 
induction of arrhythmias.40
Hypertrophied hearts with diffuse fibrosis and 
microangiopathy utilize oxygen less efficiently and are more 
likely to have disordered electrical conduction. During times 
of increased stress, the myocardium becomes ischemic and 
should have a lower threshold for fibrillation. Unfortunately, 
few case series have been able to publish the initial cardiac 
rhythms found at the scene of cocaine-associated EXD 
fatalities. One report documents 18 fatal EXD cases with 
13 primary cardiac rhythms confirmed by emergency 
personnel.6 Only one victim was confirmed to have ventricular 
tachycardia and none were found to have ventricular 
fibrillation. If primary arrest was strongly associated with 
sudden death in excited delirium, it would be expected that 
more victims would have presented with the above-mentioned 
abnormal rhythms. However, this case series was limited 
because the exact time delays in determining initial cardiac 
rhythms on arrival of emergency medical services to the 
scene was not available; thus, it is impossible to calculate 
how many of the patients might have progressed from 
ventricular tachycardia/fibrillation to asystole. Nevertheless, 
the molecular, cellular and anatomic alterations induced by 
chronic higher-dose cocaine use might explain why very low 
cocaine levels can be lethal in EXD victims.  
MANAGEMENT
While our understanding of EXD is expanding, the 
disorder still presents significant challenges to emergency first 
responders and physicians. Recent research has demonstrated 
unique cellular and neurochemical alterations in EXD victims, 
leading to dopamine excess and autonomic hyperactivity. EXD 
victims display extreme agitation, aggression, unexpected 
physical strength and florid psychosis. Emergency physicians 
must recognize the danger posed by these patients and should 
act in an expeditious and aggressive manner to avoid medical 
complications including metabolic acidosis, rhabdomyolysis, 
hyperthermia, multisystem failure and/or death. To address 
these clinical findings, we propose a treatment protocol that 
includes rapid sedation, followed closely by external cooling, 
intravenous (IV) fluids, monitoring, and treatment of potential 
medical complications. 
Given the violent and unpredictable nature of EXD 
victims, rapid sedation is likely essential to positive outcomes. 
Furthermore, if autonomic hyperactivity and aberrant 
dopamine processing is to blame for the clinical presentation 
of EXD, then the ideal drug(s) needs to “turn off” the 
catecholamine cascade and rapidly sedate the patient. Several 
types of drugs could fulfill these requirements. Neuroleptics, 
benzodiazepines, or both in combination are commonly used 
in the management of agitated patients; however, to date, there 
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are no published double-blind, randomized, placebo-controlled 
trials to confirm the efficacy and safety of antipsychotic 
medications to manage acute delirium.41 One study of 111 
violent and agitated patients by Nobay et al42 compared 
efficacy and side effect profiles of intramuscular (IM) 
midazolam (5mg), lorazepam (2mg) and haloperidol (5mg) 
randomly assigned to the study participants. They concluded 
that midazolam had a significantly shorter onset (18.3 +/- 14 
minutes) and more rapid time to arousal. Several studies found 
a significant advantage in combining two or more drugs to 
achieve maximal sedation. For instance, Battaglia et al43 and 
Bieniek et al44 documented superior efficacy and similar side 
effect profile for a combination haloperidol and lorazepam 
versus either drug alone. 
Despite the proven efficacy and safety record of 
neuroleptics and benzodiazepines, they require at least 10-15 
minutes for sedation. EXD victims may not have minutes to 
spare as they continue to struggle against law enforcement or 
physical restraints in a state of hyperthermia and metabolic 
acidosis. With the particulars of EXD in mind, we propose 
intramuscular ketamine as an alternative sedating agent 
worthy of consideration. It is a drug that can be administered 
IM (4-5 mg/kg/dose; onset of action: 3-4 minutes) or IV (1-2 
mg/kg/dose; onset of action: 30 seconds), does not require 
endotracheal intubation, and reliably produces rapid analgesia, 
sedation, and amnesia via direct action on the cortex and 
limbic system. The use of ketamine for procedural sedation in 
the pediatric ED and rural operating rooms is popular and has 
a proven record of efficacy and safety.45 With 25 years surgical 
experience in the South Pacific, Reich et al46 documented that 
ketamine was effectively used to sedate 866 unmonitored 
patients without serious complications. 
Adult data on ketamine use in the ED is sparse, but 
one recent literature review by Strayer et al47 attempted to 
determine ketamine’s adverse effect profile when used for 
procedural sedation. The analysis revealed that IM ketamine 
reliably produced adequate sedation to facilitate painful 
procedures with few side effects. Emergence phenomenon 
was documented in 10-20% of patients; but if ketamine was 
administered with a rapidly metabolized benzodiazepine (i.e. 
midazolam), then the effects were reduced significantly. In a 
unique retrospective study of 11 combative trauma patients, 
Melamed et al48 found that sedation with ketamine, with or 
without midazolam, was effective in all cases. Ketamine 
was administered intravenously for sedation by prehospital 
providers during an average transport time of 114 minutes. 
Although this report is based on a very small sample size, the 
authors reported no adverse events and suggest that ketamine 
might be an ideal intervention for the combative patient.
Although concerns about ketamine causing increased 
intracranial pressure and/or laryngospasm and subsequent 
airway obstruction have lessened, the agitated EXD victim 
represents a unique patient group for future analysis of the 
drug.45,49 Furthermore, if a catecholamine surge is at least 
partially responsible for the medical and psychiatric symptoms 
of EXD victims, then ketamine might actually exacerbate 
the underlying problem by acting as a mild stimulant of the 
cardiovascular system.46 Therefore, ketamine’s most lauded 
characteristic of having no cardiovascular, respiratory or 
airway protective reflex depression, might also be cause for 
concern. One could imagine a scenario in which ketamine’s 
rapid and superior sedation might lure the emergency 
physician into a false sense of security while the EXD 
patient is quietly decompensating. Perhaps the potential 
cardiovascular stimulation could be averted by using a 
β-adrenoreceptor blocker immediately after sedation with 
ketamine, as suggested by the results of a recent in vitro 
study using human atrial myocardium.50 Despite the promise 
of ketamine, more structured research is needed to establish 
its safety and efficacy for emergent sedation of the agitated 
patient.
 In addition to adequate sedation, several protective 
measures must be taken to increase the chances of survival 
in persons presenting with EXD. Proper management should 
arrest the catecholamine cascade quickly. Medical evaluation 
should begin promptly and include basic monitoring (IV 
access, pulse oximetry and oxygen), radiographs, blood 
tests and a focused physical exam. As mentioned previously, 
EXD victims present with autonomic hyperactivity, which 
often leads to metabolic acidosis, hyperthermia, and 
rhabdomyolysis. This clinical picture is similar enough to that 
of malignant hyperthermia (MH) and neuroleptic malignant 
syndrome (NMS) that dantrolene could be considered as 
another useful adjunctive therapy. One informative case report 
described a 25 year old patient with cocaine-excited delirium 
and severe acidosis who was treated with hyperventilation, 
passive cooling, sodium bicarbonate and dantrolene.51 This 
intervention lead to a swift correction of the acidosis and the 
patient survived. Dantrolene is a hydantoin derivative that 
abolishes excitation-contraction coupling of muscle cells by 
blocking calcium release from intracellular storage in the 
sacroplasmic reticulum. It has been used successfully for 
years by anesthesiologists to treat MH and NMS; however, its 
use in emergent situations is limited by poor water solubility 
and difficulties in rapidly preparing a suitable solution for IV 
administration.52,53   
 
CONCLUSION
EXD is a unique medical issue characterized by the acute 
onset of agitation, aggression, distress, and possibly sudden 
death. While the contribution of restraint, struggle and the 
use of electrical conduction devices to the cause of death 
raises controversy, recent research points toward central 
nervous system dysfunction of dopamine signaling as a cause 
of the delirium and fatal autonomic dysfunction. Victims 
of EXD usually die from cardiopulmonary arrest, although 
the exact cause of such arrest is likely multifactorial and 
chronic. Unfortunately, an adequate treatment plan has yet 
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to be established, although rapid sedation, followed closely 
by external cooling, IV fluids, monitoring, and treatment of 
potential medical complications is likely critical to decrease 
morbidity and mortality. Neuroleptics, benzodiazepines and 
ketamine are among the potent sedating agents that have been 
proposed to stabilize EXD victims. While there is still much 
to be discovered about the pathophysiology and treatment, it is 
hoped that this extensive review will provide both police and 
medical personnel with the information necessary to recognize 
and appropriately respond to EXD. 
Address for Correspondence:  Sean O. Henderson, Department of 
Emergency Medicine, LAC + USC Medical Center, 1200 N. State 
Street Room 1011, Los Angeles, CA 90033. Email: sohender@
hsc.usc.edu
Conflicts of Interest: By the WestJEM article submission agreement, 
all authors are required to disclose all affiliations, funding sources, 
and financial or management relationships that could be perceived 
as potential sources of bias. The authors disclosed none.
REFERENCES
1.  Sztajnkrycer MD, Baezz AA. Cocaine, excited delirium and sudden 
unexpected death. Emerg Med Serv. 2005; 34(4):77-81.
2.  Wetli CV, Mash D, Karch SB. Cocaine-associated agitated delirium 
and neuroleptic malignant syndrome. Am J Emerg Med. 1996; 
14(4):425-8.
3.  Wetli CV, Fishbain DA. Cocaine-induced psychosis and sudden 
death in recreational cocaine users. J Forensic Sci. 1985; 30(3):873-
80.
4.  Ruttenber AJ, Lawler-Heavner J, Yin M, et al. Fatal excited delirium 
following cocaine use: epidemiologic findings provide new evidence 
for mechanisms of cocaine toxicity. J Forensic Sci. 1997; 42(1):25-31.
5.  Samuel E, Williams RB, Ferrell RB. Excited Delirium: Consideration 
of selected medical and psychiatric issues. Neuropsychiatric Disease 
and Treatment. 2009; 5:61-6.
6.  Stratton SJ, Rogers C, Brickett K, et al. Factors associated with 
sudden death of individuals requiring restraint for excited delirium. 
Am J Emerg Med. 2001; 19(3):187-91.
7.  Fink M. Delirious mania. Bipolar Disord. 1999; 1(1):54-60.
8.  Morrison A, Sadler D. Death of a psychiatric patient during physical 
restraint. Med Sci Law. 2001; 41(1):46-50.
9.  Pollanen MS, Chiasson  DA, Cairns JT, et al. Unexpected death 
related to restraint for excited delirium: a retrospective study of 
deaths in police custody and in the community. CMAJ. 1998; 
158(12):1603-7.
10.  O’Halloran RL, Lewman LV. Restraint asphyxiation in excited 
delirium. Am J Forensic Med Pathol. 1993; 14(4):289-95.
11.  Ruttenber AJ, McAnally HB, Wetli CV. Cocaine-associated 
rhabdomyolysis and excited delirium: different stages of the same 
syndrome. Am J Forensic Med Pathol. 1999; 20(2):120-7.
12.  Stephens BG, Jentzen JM, Karch S, et al. Criteria for the 
interpretation of cocaine levels human biological samples and their 
relation to the cause of death. Am J Forensic Med Pathol. 2004; 
25:1-10.
13.  Staley JK, Talbot JZ, Ciliax BJ, et al. Radioligand binding and 
immunoautoradiographic evidence for lack of toxicity to dopaminergic 
nerve terminals in human cocaine overdose victims. Brain Res. 1997; 
747(2):219-29.
14.  Mash DC, Ouyang Q, Pablo J, et al. Cocaine abusers have an 
overexpression of α-synuclein in dopamine neurons. J Neurosci. 
2003; 23(7):2564-71.
15.  Little KY, McLaughlin DP, Zhang L, et al. Brain dopamine transporter 
messenger RNA and binding sites in cocaine users: a postmortem 
study. Arch Gen Psychiatry. 1998; (55):793-9.
16.  Malison RT, Best SE, Van Dyck CH, et al. Elevated striatal dopamine 
transporters during acute abstinence as measured by [123I]Beta-CIT 
SPECT. Am J Psychiatry. 1998; (155):832-4.
17.  Wilson JM, Levey AI, Bergeron C, et al. Striatal dopamine, dopamine 
transporter, and vesicular monoamine transporter in chronic cocaine 
users. Ann Neurol. 1996; 40:428-39.
18.  Mash DC, Staley JK. D3 dopamine and kappa opioid receptor 
alterations in human brain of cocaine-overdose victims. Ann N Y 
Acad Sci. 1999; 877:507-22.
19.  Staley JK, Welti CV, Ruttenber AJ, et al. Altered dopaminergic 
synaptic markers in cocaine psychosis and sudden death. NIDA Res 
Monogr Series. 1995; 153:491.
20.  Schmauss C, Haroutunian V, Davis KL, et al. Selective loss of 
dopamine D3-type receptor mRNA expression in parietal and motor 
cortices of patients with chronic schizophrenia. Proc Natl Acad Sci. 
1993; 90(19):8942-6.
21.  Mash DC, Pablo J, Ouyang Q, et al. Dopamine transport function is 
elevated in cocaine users. J Neurochem. 2002; 81(2):292-300.
22.  Pitts DK, Marwah J. Cocaine modulation of central monoaminergic 
neurotransmission. Pharmacol Biochem Behav. 1987; 26(2):453-61.
23.  Rocha BA, Fumagaffi F, Gainetdinov RR, et al. Cocaine self-
administration in dopamine-transporter knock-out mice. Nat Neurosci. 
1998;1(2):132-7.
24.  Mash DC, Staley JK, Izenwasser S, et al. Serotonin transporters 
upregulate with chronic cocaine use. J Chem Neuroanat. 2000; 20(3-
4):271-80.
25.  Mash DC, Duque L, Pablo J, et al. Brain biomarkers for identifying 
excited delirium as a cause of sudden death. Forensic Sci Int. 
2009;190(1-3):e13-9. Epub 2009 Jun 21.
26.  Stratton SJ, Rogers C, Green K. Sudden death in individuals in 
hobble restraints during paramedic transport. Ann Emerg Med. 1995; 
25(5):710-2.
27.  Karch SB. Cardiac arrest in cocaine users. Am J Emerg Med. 1996; 
14(1):79-8.
28.  Strote J, Range Hutson H. Taser use in restraint-related deaths. 
Prehosp Emerg Care. 2006; 10(4):447-50.
29.  Vilke GM, Sloane C, Levine S, et al. Twelve-lead electrocardiogram 
monitoring of subjects before and after voluntary exposure to the 
Taser X26. Am J Emerg Med. 2008; 26:1-4.
Excited Delirium  Takeuchi et al.Volume XII, no. 1  :  February 2011  83  Western Journal of Emergency Medicine
30.  Levine S, Sloane, C, Chan T, et al. Cardiac monitoring of subjects 
exposed to the Taser. Prehosp Emerg Care. 2006; 10(1):130.
31.  Barnes DG, Winslow III JE, Alson RL, et al. Cardiac effects of the 
Taser conducted energy weapon. Ann Emerg Med. 2006; 48(4 Supp 
1):S102.
32.  Chan TC, Vilke GM, Neuman T, et al. Restraint position and 
positional asphyxia. Ann Emer Med. 1997; 30(5):578-86.
33.  Chan TC, Neuman T, Clausen J, et al. Weight Force During Prone 
Restraint and Respiratory Function. Am J Forensic Med Pathol. 
2004; 25(3):185-9.
34.  Glatter K, Karch SB. Positional Asphyxia: inadequate oxygen, or 
inadequate theory. Forensic Sci Int. 2004; 141(2-3):201-2.
35.  Karch S. Cocaine cardiovascular toxicity. South Med J. 2005; 
98(8):794-9.
36.  Bricker ME, Willard JE, Eichhorn EJ, et al. Left ventricular hypertrophy 
associated with chronic cocaine abuse. Circulation. 1991; 84:1130-5.
37.  Karch S, Green G, Young S. Myocardial hypertrophy and coronary 
artery disease in male cocaine users. J Forensic Sci. 1995; 40:591-6.
38.  Besse S, Assayag P, Latour C, et al. Myocardial effects of acute and 
chronic cocaine treatment. Circulation. 1994; 90(4, pt 2):I-580 (abstr).
39.  Nassogne MC, Evrard P, Courtoy PJ. Selective direct toxicity of 
cocaine on fetal mouse neurons: teratogenic implications on neurite 
and apoptotic neuronal loss. Ann N Y Acad Sci. 1998; 846:51-68.
40.  Karch SB, Billingham ME. Myocardial contraction bands revisited. 
Hum Pathol. 1986; 17:9-13.
41.  Seitz DP, Gill SS, Van Zyl LT. Antipsychotics in the treatment of 
delirium: a systematic review. J Clin Psychiatry. 2007; 68(1):11-21.
42.  Nobay F, Simon BC, Levitt MA, et al. Dresden GM. A prospective, 
double-blind, randomized trial of midazolam versus haloperidol 
versus lorazepam in the chemical restraint of violent and severely 
agitated patients. Acad Emerg Med. 2004; 11(7):744-9.
43.  Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both 
for psychotic agitation? A multicenter, prospective, double-blinded, 
emergency department study. Am J Emerg Med. 1997; 15(4):335-40.
44.  Bienik SA, et al. A double-blind study of lorazepam versus the 
combination of haloperidol and lorazepam in managing agitation. 
Pharmacotherapy. 1998; 18(1):57-62.
45.  Green SM, Rothrock SG, Lynch EL, et al. Intramuscular Ketamine 
for pediatric sedation in the emergency department: safety profile in 
1,022 cases. Ann Emerg Med. 1998; 31(6):688-97.
46.  Reich DL, Silvay G. Ketamine: an update on the first twenty five-
years of clinical experience. Can J Anaesth. 1989; 36(2):186-97.
47.  Strayer RJ, Nelson LS. Adverse events associated with ketamine for 
procedural sedation in adults. Am J Emerg Med. 2008; 26(9):985-
1028.
48.  Melamed E, Oron Y, Ben-Avraham R, et al. The combative 
multitrauma patient: a protocol for prehospital management. Euro J 
Emerg Med. 2007; 14(5):265-8.
49.  Bourgoin A, Albanèse J, Wereszczynski N, et al. Safety of sedation 
with ketamine in severe head injury patients: comparison with 
sufentanil. Crit Care Med. 2003; 31:711.
50.  Hanouz J-L, Persehaye E, Zhu L, et al. The ionotropic and lusitropic 
effects of ketamine in isolated human atrial myocardium: the effect of 
adrenoreceptor blockade. Anesth Analg. 2004; 99:1689-95.
51.  Allam S, Noble JS. Cocaine-excited delirium and severe 
acidosis. Anesthesia. 2001; 56(4):385-6.
52.  Podranski T, Bouillon T, Schumacher PM, et al. Compartmental 
pharmacokinetics of dantrolene in adults: do malignant hyperthermia 
association dosing guidelines work? Anesth Analg. 2005; 101:1695-9.
53.  Krause T, Gerbershagen MU, Fiege M, et al. Dantrolene – a review 
of its pharmacology, therapeutic use and new developments. 
Anaesthesia. 2005; 59:364-73.
Takeuchi et al.  Excited Delirium